By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Nanoparticles. According to news reporting originating in Tehran, Iran, by NewsRx journalists, research stated, "Cutaneous leishmaniasis (CL) is endemic in the tropical and subtropical countries. Antileishmanial drugs that are traditionally used for treatment of CL are mainly toxic, ineffective for some parasite isolates, and mostly expensive."
The news reporters obtained a quote from the research from the Shaheed Beheshti University of Medical Sciences, "Previous studies showed that some metal and metal oxide nanoparticles have antimicrobial activity. Moreover, the use of nanoparticles together with ultra violet (UV) and infra red (IR) light increases toxic effects of nanoparticles by generation of reactive oxygen species (ROSS) and heat, respectively. There is little information on antileishmanial activity of nanoparticles, alone or together with UV/IR. Thus, the purpose of this research was to study antileishmanial effects of some nanoparticles including silver nanoparticles (Ag NPs), gold nanoparticles (Au NPs), titanium dioxide nanoparticles (TiO2 NPs), zinc oxide nanoparticles (ZnO NPs), and magnesium oxide nanoparticles (MgO NPs) on Leishmania major parasites under UV, IR, and dark conditions. After 24 h exposure to nanoparticles, different biological parameters such as cell viability, proliferation, infectivity, and infection index were investigated under UV/IR/dark conditions. In this study, the highest antileishmanial activity was seen for Ag NPs, followed by Au NPs, TiO2 NPs, ZnO NPs, and MgO NPs. Both UV and IR light increased antileishmanial properties of all nanoparticles. In spite of antileishmanial activity of nanoparticles under UV, IR, and dark conditions, these nanoparticles had high cytotoxicity on macrophages, which must be considered in future studies."
According to the news reporters, the research concluded: "The authors declare that the use of nanoparticles for treatment of CL may have both positive and negative consequences."
For more information on this research see: Nano-based antileishmanial agents: A toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis. Toxicology in Vitro, 2013;27(6):1896-1904. Toxicology in Vitro can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Toxicology in Vitro - www.elsevier.com/wps/product/cws_home/800)
Our news correspondents report that additional information may be obtained by contacting A. Jebali, Shahid Beheshti Univ Med Sci, Dept. of Biotechnol, Tehran 1985717453, Iran (see also Nanoparticles).
Keywords for this news article include: Iran, Asia, Tehran, Treatment, Nanotechnology, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC